Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Sovaldi (sofosbuvir) is indicated for the treatment of adult patients with genotype 1, 2, 3, or 4 chronic HCV infection without cirrhosis or with compensated cirrhosis as a component of a combination antiviral treatment regimen, and for the treatment of pediatric patients 3 years of age and older with genotype 2 or 3 chronic HCV infection without cirrhosis or with compensated cirrhosis in combination with ribavirin.
• This summary is based on the review of 22 systematic review(s)/meta-analysis(es). ^[1-22]
• GLE/PIB regimen achieved SVR12 rates of 100% in adolescents, 96% in older children, and 96% in young children. SOF/VEL regimen showed SVR12 rates of 95% in adolescents, 93% in older children, and 83% in young children. SOF/DCV regimen had an SVR12 rate of 100% in both adolescents and older children.
• SOF/VEL regimen demonstrated an overall SVR12 rate of 97.69%, with a rate of 91.94% in cirrhotic patients, and comparable efficacy between genotype 3 and non-genotype 3 infections. GLE/PIB regimen showed a pooled SVR rate of 99.4%, being a highly effective pan-genotypic option.
• SOF/VEL±Ribavirin regimen achieved an SVR12 of 91%, compared to 86.3% with SOF/LDV±Ribavirin and 82.4% with SOF/DCV±Ribavirin.
• SOF-based regimens had a pooled SVR12 rate of 97% in advanced CKD patients, with different SOF dosing strategies showing high efficacy: 92% for 400 mg alternate days, 98% for 400 mg daily, and 100% for 200 mg daily.
• Adverse events (AEs) were reported in 50% of adolescents, 53% of older children, and 72% of young children treated with sofosbuvir-based regimens, with serious adverse events (SAEs) and treatment discontinuations being uncommon (<1% in adolescents and older children, 3% in young children).
• In patients with decompensated cirrhosis, the addition of Ribavirin to SOF-based regimens significantly increased the frequency of AEs from 52.9% to 89.2%, as well as the incidence of severe events.
• Among chronic kidney disease (CKD) and hemodialysis patients, the most common AEs included fatigue (16%), anemia (15%), and nausea/vomiting (14%), with anemia being more prevalent in Ribavirin-containing regimens (46%) compared to Ribavirin-free regimens (3%).
• There is no population type or subgroup information available in the reviewed studies.